The group of Prof. Rudolf de Boer, Experimental Cardiology, RUG, has compared a large set of biomarkers in healthy subjects and in patients with chronic heart failure.
Biomarkers can be used for diagnosis, risk stratification, or management of patients with heart failure (HF). In this new publication, the group of Prof. de Boer aims to determine and compare the biological variation of a large panel of biomarkers in healthy subjects and in patients with chronic HF. The compounds measured include NT-proBNP, high-sensitivity troponin T (hsTnT), galectin-3, suppression of tumorigenicity 2 (ST2), growth differentiation factor 15 (GDF-15), and renal/neurohormonal biomarkers (aldosterone, phosphate, parathyroid hormone, plasma renin concentration, and creatinine). The assays are also available on our BiomarkerBay database.
The investigation, which was released by the Experimental Cardiology group, is described in: Variability of biomarkers in patients with chronic heart failure and healthy controls (Meijers et al., Eur J Heart Fail. 2017 Mar;19(3):357-365). Here is the full publication.
